7.0. BIBLIOGRAPHY


investigators, and sponsors, Exception from Informed Consent Requirements for Emergency Research, July 2006.


65. Richard F. Venn. Physico-Chemical properties of drugs and metabolites and their extraction from biological material, Principles and Practice of bioanalysis. 2007; 110-140.


99. Dooley M, Spencer CM, Dunn CJ. Aceclofenac, a reappraisal of its use in the management of pain and rheumatic disease, drugs, 61[9], 2001; 1351-78.


101. Lemmel EM, Leeb B, DE Bast J, Aslanidis S. Patient and physician satisfaction with aceclofenac, results of the European observational cohort study [experience with aceclofenac for inflammatory pain in daily practice], Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. 18[3], 2002; 146-53.


111. Santosh Bhalerao, Santosh Tambe, Vikas Pareek, Rupali Shinde, Lalit Kumar Gupta. A solid-liquid extraction and high performance thin layer chromatographic determination of diacerein and aceclofenac in pharmaceutical tablet dosage form. Asian journal of pharmaceutical and clinical research. 3[1], Jan-Mar 2010.


123. Roll back malaria-2007[RBM], Affordable medicines facility-malaria [AMFm], 5 may 2010.


171. Gholamreza Bahrami. High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in


201. Schapiro NA. Dude, you don't have Tourette's: Tourette’s syndrome, beyond the tics. Pediatr Nurs. 28[3], May-Jun 2002; 243-6, 249-53.


203. Determination of chlorthalidone and clonidine hydrochloride in tablets by HPLC. J Chromatogr Sci. 21[1], Jan 1983; 43-5.


234. Unger T., Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different. Am J Cardiol. 84, 1999; 9-15.


242. Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. Characterization of Conjugated Metabolites of a New Angiotensin II


